Aurigene Pharmaceutical Services Limited invests $40m For Manufacturing Facilities.

Specifications:

Name:

Aurigene Pharmaceutical Services Limited invests $40m For Manufacturing Facilities.

Location:

India

Company:

Aurigene Pharmaceutical Services Limited

Estimated Cost:

$40m

Source:

aurigeneservices.co

Introduction:

Aurigene Pharmaceutical Services Limited (Aurigene), a contract research, development, and manufacturing services organization and a step-down subsidiary of Dr.Reddy's Laboratories announces the construction of a state-of-the art development and manufacturing facility for therapeutic proteins, antibodies, and viral vectors.

Features:

As a first step of investment plan, Aurigene is investing $40m in an R&D and pilot scale facility at Genome Valley, a well-known Biotechnology Park in Hyderabad. This facility will meet the process development and clinical supply needs of global biotech companies. The facility is based on a state of-the-art design concept, allowing maximum flexibility for a multi-product, multi-platform offering across therapeutic proteins, antibodies, and viral vectors. The facility is planned to be fully operational in first half of 2024.This complements Aurigene’ s strong foundation in biotherapeutics discovery, contributing to accelerating global R&D-driven (bio)pharma companies’ biologics journey to the market by:
• Offering end-to-end and high-quality services for antibodies, proteins, and viral vectors
• Dedicated scientific team with impeccable track-record of commercializing several biosimilars
globally
• Global regulatory experience
Seamless access to commercial manufacturing – ready to sc